New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
13:37 EDTPFEEarnings Preview: Pfizer near 52-week high ahead of Q4 results
Pfizer (PFE) is scheduled to report Q4 earnings before the market open on Tuesday January 29, with a conference call scheduled for 10:00 am ET. Pfizer is a biopharmaceutical company that engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide... EXPECTATIONS: Analysts are looking for EPS of 44c on revenue of $14.4B, according to First Call. The consensus range for EPS is 43c-47c on revenue of $13.94B-$14.66B... LAST QUARTER: Pfizer reported Q3 EPS of 53c against estimates of 53c on revenue of $14B against estimates of $14.64B. At the time of its Q3 earnings release, the drug giant gave FY12 EPS guidance $2.14-$2.17 on a consensus of $2.21. Note that consensus estimates for FY12 have since been reduced to $2.16... STREET RESEARCH: On December 31, Leerink Swann said it believes Bristol-Myers (BMY) and Pfizer's (PFE) Eliquis was approved with a solid label and is positioned to be the leader for stroke prevention in atrial fibrillation... PRICE ACTION: Pfizer shares are trading close to a 52-week high of $27.30, which was reached on January 24. Shares are up about 8% in the month of January. In early afternoon trading, Pfizer shares are near flat at ~$27.
News For PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
April 20, 2015
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 15, 2015
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
April 13, 2015
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use